Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Could therapeutic cancer vaccines finally have a breakthrough in metastatic breast cancer?
One of the most intriguing Phase III trials I’m following is BRIA-ABC, evaluating Bria-IMT + retifanlimab after the regimen received FDA Fast Track designation.
Why is this trial generating attention?
Phase 2 (ASCO 2026) in heavily pretreated metastatic breast cancer (median 6 prior lines):
- Median OS: 16.6 months with the Phase III regimen
- >55% alive at 1 year
- >27% alive at 2 years
- 62% clinical benefit rate
- No treatment-related discontinuations or unexpected safety signals
Notably, BRIA-ABC enrolls patients across all metastatic breast cancer subtypes, including those with brain metastases. While it remains unlikely that every subtype will derive the same degree of benefit, this broad eligibility offers a unique opportunity to determine which biologic subsets are most responsive to therapeutic cancer vaccination and checkpoint blockade.
Will this be the trial that finally establishes a role for therapeutic cancer vaccines in metastatic breast cancer?”
Other articles featuring Matthew Kurian on OncoDaily.